Avecia Biologics Limited
Avecia Biologics Limited (Avecia) is a privately held biotechnology company. The company focuses on the development and manufacture of innovative biotechnology based medicines. The company operates through its OligiMedicine Business. Avecia works closely with its customers who are typically biotechnology or pharmaceutical companies, to aid them to achieve fast progress into and through the clinical development programme. Avecia provides its project management services to early phase microbial projects, late phase microbial projects, and mammalian cell culture projects. The company also provides process development services, including process creation, process development, scale-up and optimization, assay development, process validation and technology services. Avecia has supported the development of over 40 recombinant proteins. Its geographic operations are spread across the US and the UK. The company is headquartered at Blackley in Manchester, the UK.
The company has been acquired by MDS ( operating as Merck & Co,. Inc. in US and Canada). According to the terms and conditions of the agreement all its assets, specifically the process development and scale-up, manufacturing, quality and business support operations of Avecia Biologics located in Billingham, North East England, UK would be acquired . This acquisition has been made effective from 1st of February 2010.